VAR
Get informed when a big investor buys or sells
+ Follow| Market cap | - |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $0 |
| Beta | - |
| Outstanding Shares | 91,200,000 |
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | 3.47 |
| Price to Book Ratio | 10.42 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | - |
| Debt to Equity | 0.47 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data
This is a powerful committee controlling taxation, trade, and entitlement spending (Medicare/Medicaid). Decisions on Medicare pricing and reimbursement rates directly impact the revenue streams of hospitals, Varian's key customers, and general corporate tax policy affects profitability.
This committee allocates discretionary federal spending. Its subcommittees determine the precise funding for federal healthcare programs and research, directly influencing the budget available for Varian's customers to purchase equipment.
This committee directly regulates the FDA, which is the primary regulatory body for medical devices. Its oversight directly impacts Varian's product development, approval processes, and market access.
This committee oversees the Department of Veterans Affairs (VA). As a medical device manufacturer, Varian's products are directly impacted by VA funding decisions and procurement for veterans' healthcare.